{
    "clinical_study": {
        "@rank": "158104", 
        "acronym": "ARRDM", 
        "arm_group": {
            "arm_group_label": "asa resistant", 
            "arm_group_type": "Experimental", 
            "description": "asa resistant patients receive endovenous infusion of lysine acetylsalicylate 288 mg and if asa resistance has been reversed they have been prescribed oral soluble salt of lysine acetylsalicylate."
        }, 
        "brief_summary": {
            "textblock": "The aim of the study is assessing the prevalence of aspirin resistance in a cohort of\n      diabetic patients. Those found resistant has been undergone pharmacological tests using\n      different drug formulations to investigate the reversibility of aspirin resistance."
        }, 
        "brief_title": "Aspirin Resistance Reversibility in Diabetic Patients", 
        "condition": "Aspirin Resistance", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  diabete mellitus type 2\n\n          -  asa since 30 days at least\n\n          -  plts >150000 and <450000\n\n        Exclusion Criteria:\n\n          -  recent ACS (within 30 days)\n\n          -  anticoagulant therapy\n\n          -  haemorragic diathesis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01935193", 
            "org_study_id": "ASAR160"
        }, 
        "intervention": {
            "arm_group_label": "asa resistant", 
            "intervention_name": "lysine acetylsalicylate", 
            "intervention_type": "Drug", 
            "other_name": [
                "Flectadol", 
                "Cardirene"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Aspirin", 
                "Acetylsalicylic acid lysinate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "platelets aggregation", 
            "asa resistance"
        ], 
        "lastchanged_date": "August 30, 2013", 
        "location": {
            "contact": {
                "email": "martadoro@hotmail.com", 
                "last_name": "Marta Bisi, MD", 
                "phone": "+393476985414"
            }, 
            "facility": {
                "address": {
                    "city": "Torino", 
                    "country": "Italy"
                }, 
                "name": "San Giovanni Battista Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "Impact of Different Pharmacological Formulations on Aspirin Resistance Reversibility in Diabetics Patients", 
        "overall_contact": {
            "email": "martadoro@hotmail.com", 
            "last_name": "Marta Bisi, MD", 
            "phone": "+393476985414"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "diabetic patients found aspirin resistant receive and infusion of 288 mg of lysine acetylsalicylate and they are tested again 24 h after the infusion to investigate if aspirin resistance have been reversed.", 
            "measure": "platelets aggregation assessed by two tests (PFA100 and VerifyNow)", 
            "safety_issue": "No", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01935193"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Azienda Ospedaliera San Giovanni Battista", 
            "investigator_full_name": "Marta Bisi", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "stability of aggregation state after the reversion of aspirin resistance using oral formulation of lysine acetylsalicylate", 
            "safety_issue": "No", 
            "time_frame": "1 month"
        }, 
        "source": "Azienda Ospedaliera San Giovanni Battista", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Azienda Ospedaliera San Giovanni Battista", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}